CALL US:
022-6101 1710
sales@saffronmedia.in
HOME
NEWS
INGREDIENT MART
EVENTS
TOPICS
INTERVIEW
EDIT
News
Gujarat FDCA grants manufacturing license to Glenmark for producing API for antiviral drug favipiravir
Shardul Nautiyal, Mumbai
June 26 , 2020
The Gujarat Food and Drug Control Administration (FDCA) has given manufacturing license to Glenmark Pharmaceuticals for manufacturing API for the antiviral drug favipiravir at its Ankleshwar plant based on Drugs Controller General of India (DCGI)’s approval to manufacture favipiravir for mild and moderate COVID-19 patients in the country.
According to Gujarat FDCA Commissioner Dr H G Koshia, “It is a new drug in India for mild COVID-19 treatment. Company’s tableting unit is in Himachal Pradesh at Baddi. Post production of the API in Ankleshwar, the API will go for tableting and the drug will be available pan India in a couple of days time based on my correspondence with the company“.
We fast tracked the license approval based on DCGI permission to Glenmark Pharmaceuticals for commercial production of the drug favipiravir, he added.
Favipiravir is backed by strong clinical evidence showing encouraging results in patients with mild to moderate COVID-19. The antiviral offers broad spectrum RNA virus coverage with clinical improvement noted across age groups 20 to >90 years. Favipiravir can be used in COVID-19 patients with co-morbid conditions such as diabetes and heart disease with mild to moderate COVID-19 symptoms. It offers rapid reduction in viral load within 4 days and provides faster symptomatic and radiological improvement. Of most importance, favipiravir has shown clinical improvement of up to 88% in COVID-19 mild to moderate COVID-19 cases.
Glenmark successfully developed the active pharmaceutical ingredient (API) and the formulation for FabiFlu through its own in-house R&D team. Glenmark filed the product for clinical trial with India's drug regulator DCGI and became the first pharmaceutical company in India to receive approval for conducting phase 3 clinical trial on mild to moderate COVID-19 patients.
Favipiravir is approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections. It has a unique mechanism of action: it is converted into an active phosphoribosylated form (favipiravir-RTP) in cells and recognized as a substrate by viral RNA polymerase, thereby inhibiting RNA polymerase activity.
Share This Story
Leave a Reply
Your name (required)
Your email (required)
Website (required)
CommenT
Enter Code (Required)
INGREDIENT MART
RECENT NEWS
CCSEA asks establishments to ignore allegations by PETA India against Telangana firm
India’s rising exports to Brazil signal trust in its pharma capabilities: Pharma trade experts
DGFT extends minimum import price on soda ash imports till December 2025 to ensure fair trade
Pharmexcil opens dialogue with US on strengthening trade facilitation, market access for Indian pharmaproducts
More News...
TOPICS
Hualian finds immense potential in India’s pharma pkg machinery space
Shanghai-based Hualian Pharmaceutical Machinery Company Limited, a family-run enterprise with roots going back to 1986, ...
More News...
MAIN LINKS
OUR SERVICES
OTHER PRODUCTS
ONLINE MEDIA
About Us
Contact Us
News Archives
Product Finder
Features and Articles
News
Chronicle Pharmabiz
Food & Bevergae News
Ingredients South Asia
Media Information
Rate Card
Advertise
Copyright © 2023 Saffron Media Pvt Ltd. All Rights Reserved.
Best View in Chrome (103.0) or Firefox (90.0)